Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma.

Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB.

Clin Cancer Res. 2018 Aug 6. doi: 10.1158/1078-0432.CCR-17-3668. [Epub ahead of print]

PMID:
30082477
2.

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M.

J Hematol Oncol. 2018 May 30;11(1):71. doi: 10.1186/s13045-018-0616-2.

3.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

PMID:
29668571
4.

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.

Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA.

Oncotarget. 2017 Aug 3;8(50):87163-87173. doi: 10.18632/oncotarget.19897. eCollection 2017 Oct 20.

5.

Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.

Nejati R, Goldstein JB, Halperin DM, Wang H, Hejazi N, Rashid A, Katz MH, Lee JE, Fleming JB, Rodriguez-Canales J, Blando J, Wistuba II, Maitra A, Wolff RA, Varadhachary GR, Wang H.

Pancreas. 2017 Oct;46(9):1180-1187. doi: 10.1097/MPA.0000000000000914.

PMID:
28902789
6.

Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.

Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG.

JAMA Surg. 2017 Nov 1;152(11):1048-1056. doi: 10.1001/jamasurg.2017.2227.

PMID:
28700784
7.

Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.

Chatterjee D, Katz MH, Foo WC, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H.

Am J Surg Pathol. 2017 Aug;41(8):1097-1104. doi: 10.1097/PAS.0000000000000887.

8.

Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers.

Cox VL, Bhosale P, Varadhachary GR, Wagner-Bartak N, Glitza IC, Gold KA, Atkins JT, Soliman PT, Hong DS, Qayyum A.

Radiology. 2017 May;283(2):314-340. doi: 10.1148/radiol.2017152224. Review.

PMID:
28418819
9.

Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma.

Liu Q, Stewart J, Wang H, Rashid A, Zhao J, Katz MH, Lee JE, Fleming JB, Maitra A, Wolff RA, Varadhachary GR, Krishnan S, Wang H.

PLoS One. 2017 Feb 10;12(2):e0171985. doi: 10.1371/journal.pone.0171985. eCollection 2017.

10.

Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater.

Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG.

Ann Surg Oncol. 2017 Jul;24(7):2031-2039. doi: 10.1245/s10434-017-5777-7. Epub 2017 Jan 25.

PMID:
28124275
11.

Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?

Chadha AS, Liu G, Chen HC, Das P, Minsky BD, Mahmood U, Delclos ME, Suh Y, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH, Wang X, Thames H, Krishnan S.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):323-332. doi: 10.1016/j.ijrobp.2016.10.046. Epub 2016 Nov 8.

PMID:
28068240
12.

Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach: A Population-based Analysis.

Kutlu OC, Lee JE, Katz MH, Tzeng CD, Wolff RA, Varadhachary GR, Vauthey JN, Fleming JB, Conrad C.

Ann Surg. 2018 Mar;267(3):552-560. doi: 10.1097/SLA.0000000000002111.

PMID:
28045744
13.

Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.

Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ.

Cancer. 2017 May 15;123(6):1011-1017. doi: 10.1002/cncr.30445. Epub 2016 Nov 14.

14.

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE.

J Gastrointest Surg. 2017 Jan;21(1):164-174. doi: 10.1007/s11605-016-3265-1. Epub 2016 Oct 24.

PMID:
27778257
15.

Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.

Lee SM, Katz MH, Liu L, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H.

Am J Surg Pathol. 2016 Dec;40(12):1653-1660.

16.

Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?

Varadhachary GR, Wolff RA.

J Oncol Pract. 2016 Sep;12(9):797-805. doi: 10.1200/JOP.2016.015586. Review.

PMID:
27621332
17.

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.

Chadha AS, Skinner HD, Gunther JR, Munsell MF, Das P, Minsky BD, Delclos ME, Chatterjee D, Wang H, Clemons M, George G, Singh PK, Katz MH, Fleming JB, Javle MM, Wolff RA, Varadhachary GR, Crane CH, Krishnan S.

PLoS One. 2016 Jun 23;11(6):e0156910. doi: 10.1371/journal.pone.0156910. eCollection 2016.

18.

Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.

Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, Snyder RA, Varadhachary GR, Wolff RA, Javle M, Shroff RT, Fogelman D, Overman M, Wang H, Maitra A, Lee JE, Fleming JB, Katz MH.

Cancer. 2016 Sep 1;122(17):2671-9. doi: 10.1002/cncr.30117. Epub 2016 May 31.

19.

Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes.

Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, Wang H, Overman MJ, Varadhachary GR.

PLoS One. 2016 May 12;11(5):e0154985. doi: 10.1371/journal.pone.0154985. eCollection 2016.

20.

Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.

Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, Minsky BD, Mahmood U, Delclos ME, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH.

Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):755-65. doi: 10.1016/j.ijrobp.2015.12.003. Epub 2015 Dec 11.

21.

Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer.

Reilley MJ, Shroff R, Varadhachary GR.

Indian J Surg. 2015 Oct;77(5):403-8. doi: 10.1007/s12262-015-1361-1. Epub 2015 Oct 13.

22.

The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.

Roland CL, Katz MH, Tzeng CW, Lin H, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Vauthey JN, Crane CH, Lee JE, Fleming JB.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1221-8. doi: 10.1245/s10434-015-4854-z. Epub 2015 Sep 8.

23.

Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.

Liu L, Katz MH, Lee SM, Fischer LK, Prakash L, Parker N, Wang H, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Maitra A, Fleming JB, Estrella J, Rashid A, Wang H.

Am J Surg Pathol. 2015 Oct;39(10):1395-403. doi: 10.1097/PAS.0000000000000491.

PMID:
26200098
24.

Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma.

Xia M, Overman MJ, Rashid A, Chatterjee D, Wang H, Katz MH, Fleming JB, Lee JE, Varadhachary GR, Wolff RA, Wang H.

Hum Pathol. 2015 Sep;46(9):1315-22. doi: 10.1016/j.humpath.2015.05.012. Epub 2015 May 30.

PMID:
26165226
25.

The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy.

Fischer LK, Katz MH, Lee SM, Liu L, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Roland CL, Fleming JB, Estrella J, Rashid A, Wang H.

Histopathology. 2016 Jan;68(2):210-20. doi: 10.1111/his.12732. Epub 2015 Jun 19.

26.

Analysis of free-form radiology dictations for completeness and clarity for pancreatic cancer staging.

Marcal LP, Fox PS, Evans DB, Fleming JB, Varadhachary GR, Katz MH, Tamm EP.

Abdom Imaging. 2015 Oct;40(7):2391-7. doi: 10.1007/s00261-015-0420-1.

PMID:
25906341
27.

Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer.

Chadha AS, Kocak-Uzel E, Das P, Minsky BD, Delclos ME, Mahmood U, Guha S, Ahmad M, Varadhachary GR, Javle M, Katz MH, Fleming JB, Wolff RA, Crane CH, Krishnan S.

Acta Oncol. 2015 Jul;54(7):971-8. doi: 10.3109/0284186X.2014.1000466. Epub 2015 Jan 22.

PMID:
25608822
28.

Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer.

Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB.

Phys Biol. 2014 Nov 26;11(6):065002. doi: 10.1088/1478-3975/11/6/065002.

29.

Carcinoma of unknown primary site.

Varadhachary GR, Raber MN.

N Engl J Med. 2014 Nov 20;371(21):2040. doi: 10.1056/NEJMc1411384. No abstract available.

30.

Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.

Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB.

Ann Surg Oncol. 2015 Apr;22(4):1168-75. doi: 10.1245/s10434-014-4192-6. Epub 2014 Oct 29.

31.

Cancer of unknown primary site.

Varadhachary GR, Raber MN.

N Engl J Med. 2014 Aug 21;371(8):757-65. doi: 10.1056/NEJMra1303917. Review. No abstract available.

PMID:
25140961
32.

Occult primary, version 3.2014.

Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Jul;12(7):969-74.

PMID:
24994917
33.

Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma.

Guo R, Overman M, Chatterjee D, Rashid A, Shroff S, Wang H, Katz MH, Fleming JB, Varadhachary GR, Abbruzzese JL, Wang H.

Hum Pathol. 2014 May;45(5):1015-23. doi: 10.1016/j.humpath.2013.12.016. Epub 2014 Jan 17.

PMID:
24746206
34.

Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?

Fogelman DR, Holmes H, Mohammed K, Katz MH, Prado CM, Lieffers J, Garg N, Varadhachary GR, Shroff R, Overman MJ, Garrett C, Wolff RA, Javle M.

J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):307-13. doi: 10.1007/s13539-014-0145-y. Epub 2014 Apr 17.

35.

Transport properties of pancreatic cancer describe gemcitabine delivery and response.

Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming JB.

J Clin Invest. 2014 Apr;124(4):1525-36. doi: 10.1172/JCI73455. Epub 2014 Mar 10.

36.

Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?

Halperin DM, Varadhachary GR.

Curr Oncol Rep. 2014 Feb;16(2):366. doi: 10.1007/s11912-013-0366-9. Review.

PMID:
24445498
37.

Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.

Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH.

J Gastrointest Surg. 2014 Jan;18(1):16-24; discussion 24-5. doi: 10.1007/s11605-013-2412-1. Epub 2013 Nov 16.

PMID:
24241967
38.

Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification.

Tzeng CW, Katz MH, Fleming JB, Lee JE, Pisters PW, Holmes HM, Varadhachary GR, Wolff RA, Abbruzzese JL, Vauthey JN, Aloia TA.

J Gastrointest Surg. 2014 Jan;18(1):146-55; discussion 155-6. doi: 10.1007/s11605-013-2371-6. Epub 2013 Oct 16.

PMID:
24129825
39.

Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.

Chatterjee D, Katz MH, Rashid A, Estrella JS, Wang H, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB, Wang H.

Histopathology. 2013 Dec;63(6):841-51. doi: 10.1111/his.12234. Epub 2013 Sep 20.

40.

Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.

Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, Aloia TA, Vauthey JN, Fleming JB, Katz MH.

HPB (Oxford). 2014 May;16(5):430-8. doi: 10.1111/hpb.12154. Epub 2013 Aug 29.

41.

Rational study endpoint(s) for preoperative trials in pancreatic cancer: pathologic response rate, margin negative resection, overall survival or 'all of the above'?

Varadhachary GR, Evans DB.

Ann Surg Oncol. 2013 Nov;20(12):3712-4. doi: 10.1245/s10434-013-3165-5. Epub 2013 Aug 14. No abstract available.

PMID:
23943023
42.

Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset.

Varadhachary GR, Karanth S, Qiao W, Carlson HR, Raber MN, Hainsworth JD, Greco FA.

Int J Clin Oncol. 2014;19(3):479-84. doi: 10.1007/s10147-013-0583-0. Epub 2013 Jun 28.

PMID:
23813044
43.

Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis.

Tzeng CW, Abbott DE, Cantor SB, Fleming JB, Lee JE, Pisters PW, Varadhachary GR, Abbruzzese JL, Wolff RA, Ahmad SA, Katz MH.

Ann Surg Oncol. 2013 Jul;20(7):2197-203. doi: 10.1245/s10434-013-2889-6. Epub 2013 Feb 14.

PMID:
23408126
44.

The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.

Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S500-8. doi: 10.1245/s10434-013-2882-0. Epub 2013 Feb 10.

PMID:
23397153
45.

Adjuvant chemotherapy for resected periampullary adenocarcinoma.

Overman M, Wang H, Varadhachary GR.

JAMA. 2012 Nov 14;308(18):1855; author reply 1855-6. doi: 10.1001/jama.2012.13952. No abstract available.

PMID:
23149995
46.

Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement.

Abbott DE, Merkow RP, Cantor SB, Fleming JB, Varadhachary GR, Crane C, Bentrem DJ, Bilimoria KY.

Ann Surg Oncol. 2012 Nov;19(12):3659-67. doi: 10.1245/s10434-012-2610-1. Epub 2012 Sep 11.

PMID:
22965567
47.

Preoperative therapies for resectable and borderline resectable pancreatic cancer.

Varadhachary GR.

J Gastrointest Oncol. 2011 Sep;2(3):136-42. doi: 10.3978/j.issn.2078-6891.2011.030.

48.

Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival.

Nystrom SJ, Hornberger JC, Varadhachary GR, Hornberger RJ, Gutierrez HR, Henner DW, Becker SH, Amin MB, Walker MG.

Oncotarget. 2012 Jun;3(6):620-8.

49.

Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection.

Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN, Pisters PW, Lee JE, Rice DC, Hofstetter WL, Wolff RA, Varadhachary GR, Wang H, Katz MH.

J Gastrointest Surg. 2012 Sep;16(9):1696-704. doi: 10.1007/s11605-012-1912-8. Epub 2012 May 30.

50.

Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration.

Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, Wolff RA, Abbruzzese JL, Lee JE, Fleming JB.

J Am Coll Surg. 2012 Jul;215(1):41-51; discussion 51-2. doi: 10.1016/j.jamcollsurg.2012.03.024. Epub 2012 May 18.

Supplemental Content

Loading ...
Support Center